iMarketKorea Invests 20 Billion KRW in New Drug Development Company GI Innovation

"Discover New Business Opportunities in Healthcare and Strengthen Business Portfolio"

[Asia Economy Reporter Kim Cheol-hyun] Imarket Korea, a subsidiary of Interpark, has stepped up efforts to strengthen its healthcare portfolio through increased investment in promising bio companies.

Imarket Korea announced on the 6th that it signed a contract earlier this month to invest 20 billion KRW in the innovative new drug development company GI Innovation. Through this contract, Imarket Korea secured 600,000 common shares of GI Innovation.

GI Innovation, established in 2017, is an innovative new drug development company that has attracted industry attention by successfully completing two consecutive technology transfer contracts worth 1 trillion KRW within three years of its founding. Imarket Korea is conducting healthcare business through its pharmaceutical and medical consumables distribution subsidiaries Anyun Care and Guardian. Recently, it jointly established Interpark Bio Conversion, an innovative new drug development company, with its parent company Interpark, and is also expanding strategic investments in promising healthcare companies.

An Imarket Korea official said, "GI Innovation is a company with differentiated technology in developing innovative new drugs such as immuno-oncology and allergy treatments," adding, "Imarket Korea will continue to discover new business opportunities in the healthcare sector and further strengthen its business portfolio."

This content was produced with the assistance of AI translation services.